Patrys’ Contract Development Manufacturing Organization (CDMO) has advised that its specification testing for the drug substance produced in the recent manufacturing run of PAT-DX1 is ongoing and is now expected to be complete by the end of July 2024, which is one month later than was anticipated. This specification testing must be successfully completed for the drug material to be released for use in clinical trials.
